NVAX Key Statistics, Chart & Performance
The current stock price of NVAX is 6.86 USD. In the past month the price decreased by -10.79%. In the past year, price decreased by -23.27%.
NVAX Latest News, Press Relases and Analysis
NVAX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.2 | 404.22B | ||
| AMGN | AMGEN INC | 15.55 | 183.17B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.35 | 116.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.06 | 75.97B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 912.43 | 61.48B | ||
| INSM | INSMED INC | N/A | 43.73B | ||
| NTRA | NATERA INC | N/A | 33.41B | ||
| BIIB | BIOGEN INC | 10.87 | 26.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.34 | 20.85B | ||
| INCY | INCYTE CORP | 15.65 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.19B |
Related stock screener links
About NVAX
Company Profile
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company is headquartered in Gaithersburg, Maryland and currently employs 952 full-time employees. The company is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. The company provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Company Info
NOVAVAX INC
700 Quince Orchard Road
Gaithersburg MARYLAND 20878 US
CEO: Stanley C. Erck
Employees: 952
Phone: 12402682000
NOVAVAX INC / NVAX FAQ
Can you describe the business of NOVAVAX INC?
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company is headquartered in Gaithersburg, Maryland and currently employs 952 full-time employees. The company is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. The company provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Can you provide the latest stock price for NOVAVAX INC?
The current stock price of NVAX is 6.86 USD. The price increased by 0.29% in the last trading session.
Does NOVAVAX INC pay dividends?
NVAX does not pay a dividend.
How is the ChartMill rating for NOVAVAX INC?
NVAX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the market cap for NOVAVAX INC?
NOVAVAX INC (NVAX) has a market capitalization of 1.11B USD. This makes NVAX a Small Cap stock.
Can you provide the upcoming earnings date for NOVAVAX INC?
NOVAVAX INC (NVAX) will report earnings on 2026-02-25, after the market close.
Who owns NOVAVAX INC?
You can find the ownership structure of NOVAVAX INC (NVAX) on the Ownership tab.
NVAX Technical Analysis
NVAX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to NVAX. There are concerns on the financial health of NVAX while its profitability can be described as average.
NVAX Financial Highlights
Over the last trailing twelve months NVAX reported a non-GAAP Earnings per Share(EPS) of 1.47. The EPS increased by 165.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 32.1% | ||
| ROA | 28.96% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NVAX Forecast & Estimates
15 analysts have analysed NVAX and the average price target is 13.9 USD. This implies a price increase of 102.59% is expected in the next year compared to the current price of 6.86.
For the next year, analysts expect an EPS growth of 241% and a revenue growth 55.73% for NVAX